[1]
N. Rahim, “Bispecific CAR-T vs. BCMA-Specific CAR-T: Advancing Treatment for Relapsed/Refractory Multiple Myeloma”, HSET, vol. 153, pp. 42–47, Sept. 2025, doi: 10.54097/wvmnsh51.